Should I buy or sell Assembly Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks .

What is Assembly Biosciences' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Assembly Biosciences' stock. Their ASMB share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 102.0% from the stock's current price. View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts .

How have ASMB shares performed in 2023?

Assembly Biosciences' stock was trading at $1.30 at the beginning of 2023. Since then, ASMB stock has decreased by 42.9% and is now trading at $0.7426. View the best growth stocks for 2023 here .

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 649,700 shares, a drop of 17.3% from the October 31st total of 785,300 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company's shares are short sold. View Assembly Biosciences' Short Interest .

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ASMB earnings forecast .

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com . John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI) , Exelixis (EXEL) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) , AVEO Pharmaceuticals (AVEO) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , BioCryst Pharmaceuticals (BCRX) , Gilead Sciences (GILD) and Blueprint Medicines (BPMC) .

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (0.30%), Acadian Asset Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison , Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer , William E Iv Delaney and William E Iv Delaney . View institutional ownership trends .

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Assembly Biosciences Stock Price, News & Analysis (NASDAQ:ASMB)

$0.76

+0.02 (+2.21%)

(As of 11:21 AM ET)

Compare

Today's Range: $0.72
▼
$0.76
50-Day Range: $0.65
▼
$1.25
52-Week Range: $0.64
▼
$1.78

Volume: 97,139 shs
Average Volume: 653,471 shs
Market Capitalization: $49.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Assembly Biosciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 102.0% Upside
$1.50 Price Target
Short Interest: Healthy
2.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.71
Upright™ Environmental Score
News Sentiment: 0.05
Based on 43 Articles This Week
Insider Trading: Selling Shares
$3,403 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.19) to ($1.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

305th out of 960 stocks

Pharmaceutical Preparations Industry

93rd out of 381 stocks

3.0

Analyst's Opinion

Consensus Rating
Assembly Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Assembly Biosciences has a forecasted upside of 102.0% from its current price of $0.74.
Amount of Analyst Coverage
Assembly Biosciences has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.84% of the float of Assembly Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Assembly Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Assembly Biosciences has recently decreased by 17.27%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Assembly Biosciences does not currently pay a dividend.
Dividend Growth
Assembly Biosciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Assembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Assembly Biosciences is -0.71.

1.7

News and Social Media Coverage

News Sentiment
Assembly Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 43 news articles for Assembly Biosciences this week, compared to 23 articles on an average week.
MarketBeat Follows
Only 1 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,403.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Assembly Biosciences is held by insiders.
Percentage Held by Institutions
Only 19.92% of the stock of Assembly Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($1.19) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Assembly Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Assembly Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Assembly Biosciences has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Assembly Biosciences Stock (NASDAQ:ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASMB Stock News Headlines

December 8, 2023 | msn.com

AIMIM Leader Akbaruddin Owaisi Likely To Be Appointed As The Pro-Tem Speaker Of Telangana Assembly

December 7, 2023 | msn.com

GOP Activist Carl DeMaio to Run for Assembly Seat, Quit KOGO Radio Show

December 8, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

December 7, 2023 | news.yahoo.com

Worst snow 'by far': Anchorage Assembly members and Bronson administration debate ways to improve plowing

December 7, 2023 | msn.com

National Assembly to hold revote on four vetoed bills

December 7, 2023 | msn.com

Canada's Assembly of First Nations elects new leader

December 7, 2023 | msn.com

Up to 1200 layoffs expected at Toledo Assembly Complex, Stellantis says

December 7, 2023 | msn.com

GOP Activist and Former SD Councilman Carl DeMaio to Seek East County Assembly Seat

December 8, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

December 7, 2023 | news.yahoo.com

Comfort and joy: Seafood, warmth come together on new winter menu at The Jones Assembly

December 7, 2023 | msn.com

Assembly of First Nations assembly continues without electing new national chief

December 7, 2023 | msn.com

Police stop Amaewhule faction from accessing Rivers State House of Assembly complex

December 7, 2023 | msn.com

Meeting on future of States Assembly

December 7, 2023 | msn.com

Doctors Turn Netas: 15 Super Speciality Medics Becomes MLA After Big Win In Telangana Assembly Elections 2023

December 6, 2023 | msn.com

Assembly of First Nations election kicks off with no winner on 1st ballot

December 6, 2023 | msn.com

No first-ballot winner as Assembly of First Nations seeks its next national chief

December 6, 2023 | msn.com

New Congressional maps head to General Assembly for final approval

December 6, 2023 | msn.com

Rivers Assembly gets new Majority Leader, Chief Whip

December 6, 2023 | msn.com

Rivers Assembly crisis: Faction defies court order, holds sitting

December 5, 2023 | msn.com

Q&A: Assembly’s Labor committee chair prioritizes women, senior workers

December 5, 2023 | msn.com

Georgia General Assembly Approves New Legislative Maps

December 5, 2023 | msn.com

Meet the candidates vying to be the national chief of the Assembly of First Nations

December 5, 2023 | ca.news.yahoo.com

Assembly of First Nations meeting kicks off as election of new national chief looms

December 5, 2023 | msn.com

Nasarawa Assembly passes N8.2bn 2023 Supplementary Budget

December 5, 2023 | msn.com

Adamawa Assembly raises judicial officers’ retirement age to 65

December 5, 2023 | msn.com

Assembly of First Nations vote to elect new chief: Here’s what you need to know

December 5, 2023 | msn.com

BJP's Assembly poll victories due to Centre's money power, agencies, EC, media: Mehbooba Mufti

See More Headlines

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:ASMB
CUSIP: 92282210
CIK: 1426800
Web: www.assemblybio.com
Phone: (833) 509-4583
Fax: 646-706-5101
Employees: 68
Year Founded: 2005

Price Target and Rating

Average Stock Price Target: $1.50
High Stock Price Target: $1.50
Low Stock Price Target: $1.50
Potential Upside/Downside: +107.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -116.42%
Return on Assets: -95.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.96
Quick Ratio: 6.96

Sales & Book Value

Annual Sales: $6.25 million
Price / Sales: 7.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.69 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 65,709,000
Free Float: 62,818,000
Market Cap: $47.46 million
Optionable: Optionable
Beta: 0.50

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Jason A. Okazaki (Age 47)
CEO, President & Director
Comp: $869.28k
Dr. William E. Delaney IV (Age 51)
Ph.D., Chief Scientific Officer
Comp: $664.4k
Dr. Uri A. Lopatin M.D. (Age 51)
Co-Founder and Clinical & Scientific Advisor
Comp: $608.55k
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Shannon Ryan
Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
Ms. Jennifer A. Troia MHROD
SHRM-SCP, SPHR, Chief Human Resources Officer
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Dr. Anuj Gaggar M.D.
Ph.D., Chief Medical Officer
Mr. Thomas E. Rollins (Age 67)
Executive Officer
Comp: $472.55k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ASMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings or view top-rated stocks.
What is Assembly Biosciences' stock price target for 2024?: 1 equities research analysts have issued 1-year price targets for Assembly Biosciences' stock. Their ASMB share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 102.0% from the stock's current price.
View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts.
How have ASMB shares performed in 2023?: Assembly Biosciences' stock was trading at $1.30 at the beginning of 2023. Since then, ASMB stock has decreased by 42.9% and is now trading at $0.7426.
View the best growth stocks for 2023 here.
Are investors shorting Assembly Biosciences?: Assembly Biosciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 649,700 shares, a drop of 17.3% from the October 31st total of 785,300 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company's shares are short sold.
View Assembly Biosciences' Short Interest.
When is Assembly Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ASMB earnings forecast.
How were Assembly Biosciences' earnings last quarter?: Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?: 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.
What other stocks do shareholders of Assembly Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).
Who are Assembly Biosciences' major shareholders?: Assembly Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (0.30%), Acadian Asset Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends.
How do I buy shares of Assembly Biosciences?: Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ASMB) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Assembly Biosciences Stock Price, News & Analysis (NASDAQ:ASMB)

Assembly Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Assembly Biosciences Stock (NASDAQ:ASMB)

ASMB Stock Price History

ASMB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ASMB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™